Jacobs Levy Equity Management, Inc Nurix Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$12.02 - $21.3 $2.52 Million - $4.46 Million	-209,505 Reduced 48.23%	224,908 $4.69 Million
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $1.43 Million - $2.88 Million	184,086 Added 73.54%	434,413 $6.39 Million
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $13,799 - $34,775	3,247 Added 1.31%	250,327 $2.58 Million
Q3 2023 Nov 16, 2023	BUY	$7.86 - $10.08 $1.57 Million - $2.02 Million	200,184 Added 426.87%	247,080 $1.94 Million
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $948,717 - $1.45 Million	-109,048 Reduced 69.93%	46,896 $468,000
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $489,092 - $757,636	-57,137 Reduced 26.81%	155,944 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $1.97 Million - $2.92 Million	200,230 Added 1558.09%	213,081 $2.34 Million
Q3 2022 Nov 15, 2022	BUY	$12.33 - $19.81 $158,452 - $254,578	12,851 New	12,851 $167,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.